

SteinCares and Shilpa Biologicals to expand access to biosimilars across Latin America

25 February 2026 | News

Shilpa Biologicals will complete product development and commercial manufacturing from its facility in Dharwad



SteinCares, a leading specialty healthcare company in Latin America, and Karnataka-based Shilpa Biologicals (SB), a fully integrated biopharmaceutical subsidiary of Shilpa Medicare, have announced a strategic licensing agreement to commercialize a biosimilar across Latin America.

Under the agreement, SteinCares will hold exclusive rights to register, commercialise, and distribute biosimilar across the region while SB will complete product development and commercial manufacturing from its facility in Dharwad.

The partnership brings together SB's expertise in biologics development and high-quality commercial manufacturing with SteinCares' integrated regional platform.

Mitchell Wasserstein, CEO, SteinCares said, "This agreement reinforces our leadership in biosimilars and our role as a strategic partner for global biopharmaceutical companies seeking to enter Latin America's complex healthcare markets. By combining Shilpa's proven capabilities in biologics development and manufacturing with our integrated regional platform and deep market expertise, we are creating scalable healthcare opportunities and expanding access to innovative, cost-effective treatments across the region."

"SteinCares is a trusted partner in Latin America with proven expertise in the registration and commercialization of specialty

therapies," said Dr Sridevi Khambhampaty, CEO, Shilpa Biologicals. "Through this licensing agreement, we are entering Latin America and aim to broaden patient access to safe treatments across the region. We believe this collaboration will create meaningful value for patients, healthcare systems, and our organizations as we expand our biosimilars footprint in Latin America. This collaboration reinforces our commitment to scalable, long-term global licensing partnerships and creates a strong platform for future collaborations across key international markets and our growing biosimilars portfolio."